---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-056363"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T16:54:49.183524+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Inovio Q4 net loss $54.5M; VGX-3100 Phase 3 trial fails primary endpoint in biomarker group

## Summary
- Net loss of $54.5M ($0.22 per share) for Q4 2022; full year net loss $279.8M ($1.17 per share).
- Cash and short-term investments $253M as of Dec 31, 2022; cash runway projected into Q1 2025.
- REVEAL2 Phase 3 trial of VGX-3100 did not meet primary endpoint in biomarker-selected population (p=0.115); but achieved statistical significance in all-participants population (p=0.001).
- Positive Phase 1/2 data for INO-3107 in RRP: median decrease of 3 surgical interventions; 91% of patients saw reduction.
- Positive Phase 1b data for INO-4201 as Ebola booster: 100% of treated participants boosted humoral responses.

## SEC filing metadata
- accession: 0001193125-23-056363
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000119312523056363/0001193125-23-056363-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000119312523056363/d378213d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-056363
- JSON: https://secwatch.observer/filing/0001193125-23-056363.json
- Plain text: https://secwatch.observer/filing/0001193125-23-056363.txt

## Key facts
- Earnings Releases
  INOVIO PHARMACEUTICALS, INC. reported financial results for the quarter and year ended December 31, 2022.
  - Period: the quarter and year ended December 31, 2022
  - Result: reported results
  source text: On March 1, 2023, Inovio Pharmaceuticals, Inc. (the " Company ") issued a press release announcing its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1055726/000119312523056363/0001193125-23-056363-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.